In the end there will be more than one vaccine
The corona crisis is keeping the world in suspense. In Germany, too, biochemists are looking for vaccines against Sars-CoV-2, the causative agent of the disease Covid-19. Stefan Müller, who heads preclinical development at the biopharmaceutical company CureVac, is one of them.
Various research groups are developing vaccines against the new coronavirus Sars-CoV-2. The German company CureVac is also there. The Tübingen-based company has meanwhile hit the headlines because, according to media reports, US President Donald Trump is said to have tried to secure the rights to the vaccine – which company representatives dispute. Will the first tests on humans take place this summer? And what kind of vaccine is that exactly? A conversation with Stefan Müller, Vice President Preclinical at CureVac.
You are working on a vaccine against the new coronavirus. How far are you?
We are currently testing our vaccine candidate in the preclinical models required by law – on cell cultures as well as on rodents. However, we have already contacted the approval authorities for the first tests on humans.
When should the first human tests start?
We are in close contact with the responsible authorities and plan to inject test subjects with the vaccine for the first time in June…
